PATENT CLAIM ANALYSIS

Application Number: 16062206
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "759000"]

Abstract:
The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.

Claim (Index 30):
The method of  claim 29 , wherein the amount is a once daily amount selected from the group consisting of: 0.15 mg to 0.50 mg, 0.50 mg to 0.75 mg, 0.75 mg to 1.25 mg, 1.25 mg to 1.5 mg, 1,5 mg to 1.75 mg, 1.75 mg to 2 mg, 2 mg to 2.25 mg, 2.25 mg to 2.5 mg, 2.5 mg to 2.75 mg, 2.75 mg to 3 mg, 3 mg to 5 mg, 5 mg to 7 mg, 7 mg to 8 mg, 8 mg to 10 mg, 10 mg to 20 mg and 20 mg to 50 mg.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 94.0
- Lexical Diversity: 1.125
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15323967', '15535837', '14966427', '14438977', '13832672']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7842192293008384
- 35 USC 102 Novelty (BERT): 0.5482646613548983
- Combined Prediction Score: 0.7606237725062444
- Mean Citation Score: 342.913132
- Max Citation Score: 411.311
- Similarity Product: 247.9887296082973

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test